Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma

Nivolumab is a monoclonal antibody that blocks the interaction between programmed cell death 1 (PD1) and programmed cell death 1-ligand 1 (PD-L1), resulting in enhanced antitumor activity by the immune system. Nivolumab is currently approved by the US Food and Drug Administration (FDA) for melanoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Therese, Millett, Molly M., Zhang, Xiaoling, Jansson, Malinka, Cleveland, Rachel, Simmons, Pauline, Cherryholmes, Gregory, Carnahan, Josette, William, Josette, Spaulding, Betsy, Satnick, Ilana R., Inzunza, H. David, Taylor, Clive, Cogswell, John, Novotny, James, Oroudjev, Emin, Winther, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Reserch Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753812/
https://www.ncbi.nlm.nih.gov/pubmed/29189265
http://dx.doi.org/10.1097/PAI.0000000000000605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753812/
https://www.ncbi.nlm.nih.gov/pubmed/29189265
http://dx.doi.org/10.1097/PAI.0000000000000605

Ejemplares similares